Eli Lilly has announced the availability of its recently approved weight loss treatment, Zepbound, at pharmacies across the United States. Zepbound, an injection administered once weekly, serves as an alternative to rival obesity drugs, particularly Wegovy, facing supply issues. The weight loss drug market is anticipated to grow to about $100 billion by the end… Continue reading Eli Lilly weight loss drug Zepbound now available at pharmacies as rival Wegovy faces shortages

CVS Health has announced a significant overhaul of its prescription drug pricing model, aiming to bring greater transparency and alignment with consumer costs. The company intends to launch the new reimbursement model, named CVS CostVantage, on January 1, 2025, for commercial payors. This move reflects CVS’s commitment to reshape the traditional prescription drug pricing system,… Continue reading CVS to change how it prices prescription drugs with new pharmacy reimbursement model

The study conducted by pharmacists at Long Island University raises concerns about the accuracy and reliability of OpenAI’s ChatGPT, particularly in responding to drug-related questions. The researchers posed 39 questions related to medications to the free version of ChatGPT in May, and only 10 responses were deemed satisfactory based on established criteria. The study found… Continue reading Free ChatGPT may incorrectly answer drug questions, study says

Orchid, a reproductive technology startup, has unveiled a groundbreaking genetic test aimed at providing prospective parents undergoing in vitro fertilization (IVF) with valuable insights into their embryos. The company’s commercially available whole genome sequencing report is designed to identify genetic risks, such as birth defects, neurodevelopmental disorders, chromosomal abnormalities, and pediatric or adult-onset cancers, offering… Continue reading Reproductive startup launches test to identify an embryo’s genetic defects before an IVF pregnancy begins

Swiss pharmaceutical giant Roche is set to acquire Carmot Therapeutics, an anti-obesity drug developer, in a bid to challenge the dominance of Novo Nordisk and Eli Lilly in the global weight-loss drugs market. The deal involves a $2.7 billion cash payment to Carmot’s equity holders at the transaction’s close, with the potential for an additional… Continue reading Roche enters obesity market with Carmot takeover but drugs may not be available until 2030

Pfizer has decided to discontinue the development of its twice-daily weight loss pill, danuglipron, following a midstage clinical trial where obese patients experienced significant weight loss but also faced high rates of adverse side effects. This move comes six months after Pfizer abandoned another once-daily weight loss pill due to elevated liver enzymes. The challenges… Continue reading Pfizer’s twice-daily weight loss pill joins a long list of obesity drug flops

Novo Nordisk has filed lawsuits against two compounding pharmacies in Florida, Wells Pharmacy Network and Brooksville Pharmaceuticals, accusing them of selling impure and potentially unsafe drugs claiming to contain semaglutide, the active ingredient in Novo Nordisk’s blockbuster weight loss treatment Wegovy and diabetes medication Ozempic. The legal actions come amid shortages of Wegovy and Ozempic… Continue reading Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs

Pfizer announced on Friday that it would halt the development of the twice-daily version of its experimental weight loss pill due to high rates of adverse side effects observed in a mid-stage clinical study. Although obese patients taking the drug experienced significant weight loss, the pharmaceutical company found that many had difficulty tolerating the medication.… Continue reading Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects

Three years into the Covid-19 pandemic, the U.S. faces challenges in sustaining Covid vaccine uptake, with only 15.7% of adults having received the latest shots from Pfizer, Moderna, and Novavax as of November 18. The Centers for Disease Control and Prevention (CDC) expressed concern about the low vaccination rates, emphasizing the added protection against severe… Continue reading Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them

Health-care giants Cigna and Humana are reportedly in talks to merge, causing a decline in their stock values. The potential deal, described as a mega deal, is said to involve a stock-and-cash arrangement and could be finalized by the end of the year. With Cigna’s market value at around $77 billion and Humana’s nearly $60… Continue reading Cigna, Humana shares fall after report health-care giants are in talks to merge

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the third quarter and nine months ended September 30, 2023, and provided a corporate update.  “We recently achieved… Continue reading Alpha Cognition Announces Third Quarter and Nine Months Ended September 30, 2023, Results and Provides Corporate Update

FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX“) a nanotechnology company developing surface protection coatings, is pleased to announce that the Company will be presenting at the SHARE™ Series Monday Management Update on December 4, 2023, at 2 PM ET. The virtual fireside chat will consist of a 30-minute discussion… Continue reading FendX Technologies to Present at the SHARE(TM) Series Monday Management Update on December 4, 2023